Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 2
1987 3
1989 2
1991 1
1992 1
1998 1
2001 1
2010 1
2012 1
2014 1
2016 1
2018 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
gMS-Classifier1 does not predict disability progression in multiple sclerosis.
van Rossum JA, Killestein J, Villar LM, Riskind PN, Freedman MS, Teunissen C. van Rossum JA, et al. Among authors: riskind pn. Mult Scler. 2019 Jun;25(7):1010-1011. doi: 10.1177/1352458518798048. Epub 2018 Aug 31. Mult Scler. 2019. PMID: 30168749 Free PMC article. No abstract available.
Branching enzyme deficiency: expanding the clinical spectrum.
Paradas C, Akman HO, Ionete C, Lau H, Riskind PN, Jones DE, Smith TW, Hirano M, Dimauro S. Paradas C, et al. Among authors: riskind pn. JAMA Neurol. 2014 Jan;71(1):41-7. doi: 10.1001/jamaneurol.2013.4888. JAMA Neurol. 2014. PMID: 24248152 Free PMC article.
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators. Giovannoni G, et al. Neurology. 2016 Nov 8;87(19):1985-1992. doi: 10.1212/WNL.0000000000003319. Epub 2016 Oct 12. Neurology. 2016. PMID: 27733571 Free PMC article. Clinical Trial.
Neurologic manifestations of hypothalamic disease.
Martin JB, Riskind PN. Martin JB, et al. Among authors: riskind pn. Prog Brain Res. 1992;93:31-40; discussion 40-2. doi: 10.1016/s0079-6123(08)64561-6. Prog Brain Res. 1992. PMID: 1480755
Prolactin pulsatile characteristics in postmenopausal women.
Katznelson L, Riskind PN, Saxe VC, Klibanski A. Katznelson L, et al. Among authors: riskind pn. J Clin Endocrinol Metab. 1998 Mar;83(3):761-4. doi: 10.1210/jcem.83.3.4675. J Clin Endocrinol Metab. 1998. PMID: 9506722
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Coles AJ, et al. Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122650 Clinical Trial.
16 results